Osimertinib for resistant lung cancer improves PFS vs SoC, with 54% reduction of progression/death, plus control of… https://t.co/vdo0LzSqgj
from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://twitter.com/ecancer/status/906407386847604737
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,